Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348692 · ClinicalTrials.gov registry record · Phase 3
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
A Phase 3 study, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,195
- Enrollment target
NCT07348692: Recruiting Phase 3 study, sponsored by Sanofi.
NCT07348692 is a Phase 3 study that is actively recruiting participants, run by Sanofi. The registered enrollment target is 2,195 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (184% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07348692, a Phase 3 study, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,195 participants
- Enrollment target
Study Summary
This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age. Cohort A will include randomization to three PCV21 formulation groups or one 20vPCV comparator group (Group 1-4, approximately 896 total participants), whereas Cohort B will include randomization to three PCV21 formulation groups only (Groups 1-3, approximately 1299 total participants). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age, V06 separated from V05 by 30 days
Primary Outcome
Serotype specific IgG concentrations for all serotypes included in PCV21 vaccine as measured by electrochemiluminescence assay (ECL)
Interventions
- BIOLOGICAL PCV21 vaccine
- BIOLOGICAL 20vPCV licensed vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,195 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2028-05-29 |
| Phase | Phase 3 |
What NCT07348692 shows while recruiting
NCT07348692 is an interventional study that assigns participants to a tested intervention. Its 2,195 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (184% higher).
The record links to 0 conditions, and to 2 interventions - of which PCV21 vaccine is the first listed.
NCT07348692 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07348692 about?
NCT07348692 is a clinical study titled "Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age". This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are give...
What is the current status of trial NCT07348692?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,195 participants. The study started on 2026-01-20. Estimated completion is 2028-05-29.
What interventions are being tested in trial NCT07348692?
The interventions under investigation include: PCV21 vaccine (BIOLOGICAL), 20vPCV licensed vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07348692?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07348692's enrollment target sits among peer trials
2,195 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI